Kordzińska-Cisek Izabela, Cisek Paweł, Grzybowska-Szatkowska Ludmiła
Department of Oncology, Medical University in Lublin, Lublin, Poland.
St. John's Oncology Center in Lublin, Lublin, Poland.
Cancer Manag Res. 2020 Feb 11;12:1047-1067. doi: 10.2147/CMAR.S233431. eCollection 2020.
Salivary gland neoplasms are rare cancers of the head and neck region. Radical treatment in tumors of large salivary glands is surgery. Adjuvant treatment depends on the presence of risk factors that worsen the prognosis, but the role of these factors in patients treated by surgery with radio- or radiochemotherapy still remains unclear. The aim of the study is assessment of treatment results and identification of the risk factors affecting the prognosis in patients with tumors of large salivary glands subjected to adjuvant radio- or radiochemotherapy.
The study included 126 patients with local stage large salivary gland cancer who were treated surgically with adjuvant radio- or radiochemotherapy. The study excluded inoperable patients, patients with distant metastases, patients in a poor general condition and patients with contraindications to adjuvant treatment. They were treated between 2006 and 2016 and evaluated in terms of OS (overall survival), CSS (cancer-specific survival), RFS (relapse-free survival) and LRFS (local relapse-free survival).
During a 44-month follow-up, 5-OS, CSS, RFS and LRFS were 55%, 68%, 60% and 73%, respectively. Multivariate analysis showed that OS was influenced by the following parameters: WHO performance status, TNM stage (T and N parameters), radicality of surgery, histopathological type, applied method of radiotherapy planning and tumor volume. WHO performance status, T and N parameters of the TNM stage and large volume of elective area influenced CSS, and the T parameter of the TNM stage, the dose below 60Gy and tumor volume influenced RFS and LRFS. Chemoradiotherapy can be used in N-positive patients.
The analysis indicates that the TNM grade, histopathological type, patient's condition, radicality of the procedure, technique and dose of radiotherapy are the most important prognostic factors in these patients.
涎腺肿瘤是头颈部区域罕见的癌症。大涎腺肿瘤的根治性治疗方法是手术。辅助治疗取决于是否存在会使预后恶化的风险因素,但这些因素在接受手术联合放疗或放化疗的患者中的作用仍不明确。本研究的目的是评估接受辅助放疗或放化疗的大涎腺肿瘤患者的治疗效果,并确定影响其预后的风险因素。
本研究纳入了126例局部晚期大涎腺癌患者,这些患者接受了手术联合辅助放疗或放化疗。研究排除了无法手术的患者、有远处转移的患者、一般状况较差的患者以及有辅助治疗禁忌证的患者。他们在2006年至2016年期间接受治疗,并根据总生存期(OS)、癌症特异性生存期(CSS)、无复发生存期(RFS)和局部无复发生存期(LRFS)进行评估。
在44个月的随访期间,OS、CSS、RFS和LRFS分别为55%、68%、60%和73%。多因素分析显示,OS受以下参数影响:世界卫生组织(WHO)体能状态、TNM分期(T和N参数)、手术根治性、组织病理学类型、应用的放射治疗计划方法和肿瘤体积。WHO体能状态、TNM分期的T和N参数以及选择性区域的大体积影响CSS,TNM分期的T参数、低于60Gy的剂量和肿瘤体积影响RFS和LRFS。放化疗可用于N阳性患者。
分析表明,TNM分级、组织病理学类型、患者状况、手术根治性、放疗技术和剂量是这些患者最重要的预后因素。